Investor Presentaiton
Three Major Preclinical Platforms Drive Full-Speed Development of
Representative Molecules
Protein drug discovery and engineering
platform to enable innovative therapeutic
SINGLE B
CULTURE/CLONING
PHAGE DISPLAY
HA
Aga 2
R&D
A14T (Al for Therapeutics) to drive
innovative drug discovery for oncology,
metabolism, immunology and neurology
TARGET
CORRELATION
BIOINFORMATICS
Hanjugator™:
Modular ADC toolbox and development
platform
Develop differentiated, clinically valuable ADC products
Establish antibody and linker-payload toolbox with
independent intellectual property
Based on the Deep Data Driven Drug Discovery (5D)
platform, integrate medical informatic data to
discover new targets, mechanisms and drugs for
metabolism, inflammation, and Immune Intervention
O
Aga 1
Yeast
surface
YEAST DISPLAY
ANTIBODY
"LIBRARY"
IN-SILICO BASED
OPTIMIZATION
DEPORT
Assessment of CORS
Assessment of
Whole molecule-
BIOCOMPUTING FOR
ANTIBODY
DISCOVERY
HIGH-THROUGHPUT EXPRESSION VALIDATION AND
EARLY CMC EVALUATION
mAb/Bi/Tri
Cytokine
HLX6018 (mAb)
GARP/TGF-ẞ1
Idiopathic pulmonary fibrosis
⚫ IND accepted in China in Dec.
2023 for indications of IPF
32
Improve safety and
therapeutic window
Develop tumor
microenvironment
1
Conditionally
Released Payload-
汉联
Linker (CRPL)
platform
Hanjugator™
Modular ADC and
custom design
3
Increase ADC
4
Enzyme
Peptide
potency
Develop MP-ADC,
HC-ADC
HLX30 (bisAB)
EGFR x c-Met
Solid tumors
.
Balancing cell killing and
safety
EGFR-mutated NSCLC
HLX41 (ADC)
LIV1 ADC
Solid tumors
A14T: Al for therapeutics; MP-ADC: Multiple-Payloads ADC; HC-ADCL: High-Capacity ADC
Improve ADC
selectivity
Develop tumor targeting
+
2 payload, and tumor
microenvironment
Conditionally Activated
Antibody (CAAb)
platform
Expand indication
application for ADC
Develop new toxic and
non-toxic payload
Driven by the Biocomputing Accelerated Molecule
Design (BAMD) platform, design new drug molecules
such as peptides, nucleic acids, and optimize
antibodies, small molecule drugs, ADC payload-
linkers, etc.
Develop innovative drugs for complex diseases through
network biology and polypharmacology
HLX48 (ADC)
EGFR x c-MET ADC
Solid tumors
HLX80 (ADC)
STEAP1 ADC
Prostate cancer
HLX92 (SMC)
Polypharmacology
Primary sclerosing cholangitis, Primary biliary
cholangitis
.
•
First-in-class small molecule-drug conjugates
(SMDC) with polypharmacological function
Address unmet clinical needs in PSC and PBC
Innovative mAb
O 2024 Henlius.
Innovative small molecule
Innovative BsAb
Innovative ADC
HLX99 (SMC)
Polypharmacology
Amyotrophic lateral sclerosis
⚫ First-in-class SMDC with
polypharmacological function
.
Target unmet clinical needs
in ALS
2 HenliusView entire presentation